Immune-inflammatory and hypothalamic-pituitary-adrenal axis biomarkers are altered in patients with non-specific low back pain: A systematic review
Open Access
- 2 September 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 945513
Abstract
This systematic review aimed to investigate immune-inflammatory and hypothalamic-pituitary-adrenal (HPA) axis biomarkers in individuals with non-specific low back pain (NSLBP) compared to healthy control. The search was performed in five databases until 4 November 2021. Two reviewers independently conducted screenings, data extraction, risk of bias, and methodological quality assessment of 14 unique studies. All studies reported the source of the fluid analyzed: nine studies used serum, two used plasma, one used serum and plasma, and two studies used salivary cortisol. We found preliminary and limited evidence (only one study for each biomarker) of increased levels in growth differentiation factor 15 (GDF-15), interleukin-23 (IL-23), transforming growth factor–beta (TGF-β), and soluble tumor necrosis factor receptor 1 (sTNF-R1) in NSLBP. Inconsistent and limited evidence was identified for interleukin-10 (IL-10). Although C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor–alpha (TNF-α) levels appear to increase in NSLBP, only one study per each biomarker reported statistically significant differences. Interleukin-1 beta (IL-1β), interleukin-17 (IL-17), interferon gamma (IFN-γ), and high-sensitivity CRP (hsCRP) showed no significant differences. Regarding cortisol, one study showed a significant increase and another a significant decrease. More robust evidence between GDF-15, IL-23, TGF-β, and sTNF-R1 with NSLBP is needed. Moreover, contrary to the findings reported in previous studies, when comparing results exclusively with healthy control, insufficient robust evidence for IL-6, TNF-α, and CRP was found in NSLBP. In addition, cortisol response (HPA-related biomarker) showed a dysregulated functioning in NSLBP, with incongruent evidence regarding its directionality. Therefore, our effort is to find adjusted evidence to conclude which immune-inflammatory and HPA axis biomarkers are altered in NSLBP and how much their levels are affected.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020176153, identifier CRD42020176153.Keywords
Funding Information
- Instituto de Salud Carlos III
This publication has 58 references indexed in Scilit:
- Chronic stress, glucocorticoid receptor resistance, inflammation, and disease riskProceedings of the National Academy of Sciences of the United States of America, 2012
- Influence of depression symptoms on serum tumor necrosis factor-α of patients with chronic low back painArthritis Research & Therapy, 2010
- Influence of comorbidity with depression on interdisciplinary therapy: outcomes in patients with chronic low back painArthritis Research & Therapy, 2010
- Inflammatory response following a short-term course of chiropractic treatment in subjects with and without chronic low back painJournal of Chiropractic Medicine, 2010
- The Association Between Obesity and Low Back Pain: A Meta-AnalysisAmerican Journal of Epidemiology, 2009
- Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunityCurrent Opinion in Pharmacology, 2009
- Cytokine Mechanisms of Central Sensitization: Distinct and Overlapping Role of Interleukin-1β, Interleukin-6, and Tumor Necrosis Factor-α in Regulating Synaptic and Neuronal Activity in the Superficial Spinal CordThe Journal of Neuroscience, 2008
- Cytokines, Inflammation, and PainInternational Anesthesiology Clinics, 2007
- Chapter 3 European guidelines for the management of acute nonspecific low back pain in primary careEuropean Spine Journal, 2006
- When Good Pain Turns BadCurrent Directions in Psychological Science, 2003